Mirata BioPharma Becomes Resident Company at Johnson & Johnson Innovation JLABS

HOUSTON--()--Mirata BioPharma, LLC, an immuno-oncology company, announced today that it is now a Resident Company at Johnson & Johnson Innovation, JLABS (JLABS) at the prestigious Texas Medical Center—the world’s largest cancer center—located in Houston, TX (JLABS @ TMC).

“Our company’s Targeted Granzyme B Immunotherapy recombinant fusion protein is versatile and has therapeutic applications to multiple types of solid tumors, including breast, melanoma, and non-small cell lung cancer”

Recognized as one of the Rice Alliance’s 10 Most Promising Life Science Companies in 2017, Mirata BioPharma is a pre-clinical stage immuno-oncology company that is focused on developing the next generation of precision immuno-oncology therapeutics. Through targeted research and the development of three distinct drug candidates, Mirata aims to transform the treatment of cancer.

“Our company’s Targeted Granzyme B Immunotherapy recombinant fusion protein is versatile and has therapeutic applications to multiple types of solid tumors, including breast, melanoma, and non-small cell lung cancer,” said Keizo Koya PhD, CEO of Mirata BioPharma, LLC. “We are honored to be selected to join JLABS @ TMC and believe that our presence at here will help us accelerate the development of our innovative platform.”

JLABS is a 34,000 square-foot life science innovation center, located Houston, Texas. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation (JJI) does not take an equity stake in the companies occupying JLABS and the companies are free to develop products - either on their own, or by initiating a separate external partnership with JJI or any other company.

ABOUT MIRATA BIOPHARMA, LLC

Mirata BioPharma, LLC is a pre-clinical stage immuno-oncology company founded in January 2017. The Company entered into a license agreement with Research Development Foundation, a nonprofit supporting organization of the Clayton Foundation for Research (“Clayton Foundation”) to develop three drug candidates based on the Targeted Granzyme B Immunotherapy (TGI) platform. The TGI platform was developed by a team of Clayton Foundation investigators headed by Michael Rosenblum, PhD. Dr. Rosenblum’s research is in developing targeted immunotherapeutic approaches that maximize anti-tumor efficacy while minimizing immunosuppressive side effects. He is on the Scientific Advisory Board of Mirata BioPharma.

Contacts

Mirata BioPharma, LLC
Mito Aoki Koya, +1-781-761-0123
Executive Assistant to the CEO
mito.aoki@mirata-bio.com
www.mirata-bio.com

Recent Stories

RSS feed for Mirata BioPharma, LLC